Summary
BeOne Medicines Ltd. (ONC) filed an 8-K on April 28, 2022, primarily to disclose information related to its 2021 Annual Report filed with the Shanghai Stock Exchange and a significant clinical trial update. The company provided financial information prepared under China Accounting Standards (CAS), which differs from U.S. GAAP, along with details on R&D expenses and product inventory. Investors should note that this financial data is presented in accordance with PRC regulations and may require reconciliation for comparability with U.S. reporting standards.
Key Highlights
- 1BeiGene, Ltd. (the Company) filed its 2021 Annual Report with the Shanghai Stock Exchange, adhering to PRC listing rules and regulations.
- 2The STAR Annual Report includes detailed financial information prepared under China Accounting Standards (CAS), including gross profit margin, R&D expenses by product, and inventory levels for key products.
- 3The Company has provided supplemental information regarding R&D expenses and product inventory prepared under U.S. GAAP, along with a summary of material differences between PRC GAAP and U.S. GAAP, attached as Exhibit 99.1.
- 4The STAR Annual Report is available in Chinese on the Shanghai Stock Exchange website.
- 5An Independent Data Monitoring Committee (IDMC) determined that the global Phase 3 RATIONALE 306 trial for tislelizumab met its primary endpoint for overall survival (OS) in untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).
- 6This positive Phase 3 result for tislelizumab in combination with chemotherapy is a significant clinical development for the company.
Frequently Asked Questions
This 8-K filing serves two main purposes: to inform investors about the filing of BeiGene's 2021 Annual Report with the Shanghai Stock Exchange under PRC regulations, and to announce a positive outcome from a Phase 3 clinical trial (RATIONALE 306) for their drug tislelizumab.
The filing includes financial information from the company's 2021 Annual Report prepared under China Accounting Standards (CAS). It also provides supplemental financial information prepared under U.S. GAAP, including R&D expenses by product and inventory data, along with a reconciliation of differences between the two accounting standards.
The RATIONALE 306 trial met its primary endpoint of overall survival (OS) in a Phase 3 study for tislelizumab combined with chemotherapy in patients with previously untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC). This is a crucial positive development, suggesting potential efficacy and a pathway towards regulatory submissions for this indication.
The full 2021 Annual Report is available in Chinese on the website of the Shanghai Stock Exchange (www.sse.com.cn). The information filed with the Shanghai Stock Exchange is not directly incorporated into this 8-K filing with the SEC, other than the specific exhibits provided.